1. I rate Pfizer a sell for the next 18-24 months due to continued headwinds from Medicare Part D redesign and patent expirations. 2. Danuglipron could be a catalyst for a turnaround if late-stage trials succeed in 2025. 3. Short-term, the 6.6% yield and low valuation ratios may attract value investors.